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ORIGINAL ARTICLE
Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome
Analysis of Intestinal Biopsies
Tue Bjerg Bennike, PhD,*,†,‡ Thomas Gelsing Carlsen, MS,* Torkell Ellingsen, MD, PhD,§
Ole Kristian Bonderup, MD, PhD,k,¶ Henning Glerup, MD, PhD,k Martin Bøgsted, PhD,**,††
Gunna Christiansen, MD, DMSc,‡‡ Svend Birkelund, MD, PhD, DMSc,* Allan Stensballe, PhD,*
and Vibeke Andersen, MD, PhD†,‡,§§
Background: The etiology of the inﬂammatory bowel diseases, including ulcerative colitis (UC), remains incompletely explained. We hypothesized
that an analysis of the UC colon proteome could reveal novel insights into the disease etiology.
Methods: Mucosal colon biopsies were taken by endoscopy from noninﬂamed tissue of 10 patients with UC and 10 controls. The biopsies were either
snap-frozen for protein analysis or prepared for histology. The protein content of the biopsies was characterized by high-throughput gel-free quantitative
proteomics, and biopsy histology was analyzed by light microscopy and confocal microscopy.
Results: We identiﬁed and quantiﬁed 5711 different proteins with proteomics. The abundance of the proteins calprotectin and lactotransferrin in the
tissue correlated with the degree of tissue inﬂammation as determined by histology. However, fecal calprotectin did not correlate. Forty-six proteins were
measured with a statistically signiﬁcant differences in abundances between the UC colon tissue and controls. Eleven of the proteins with increased
abundances in the UC biopsies were associated with neutrophils and neutrophil extracellular traps. The ﬁndings were validated by microscopy, where an
increased abundance of neutrophils and the presence of neutrophil extracellular traps by extracellular DNA present in the UC colon tissue were
conﬁrmed.
Conclusions: Neutrophils, induced neutrophil extracellular traps, and several proteins that play a part in innate immunity are all increased in abundance
in the morphologically normal colon mucosa from patients with UC. The increased abundance of these antimicrobial compounds points to the stimulation
of the innate immune system in the etiology of UC.
(Inﬂamm Bowel Dis 2015;21:2052–2067)
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U lcerative colitis (UC), 1 of the 2 major forms of inﬂamma-tory bowel diseases (IBDs), is an important health problem.
The incidence rate varies between the geographic regions, and in
Europe, annual incidence rates between 0.6 and 24.3 per 105
inhabitants and prevalences rates between 4.9 and 505 per 105
inhabitants have been reported.1 Ulcerative colitis has a great
impact on the quality of life of the affected individuals and for
society due to lost labor and expenses to the health care sys-
tem.2–4 The etiology of IBD remains incompletely explained but
involves genetic and environmental factors. Genome-wide asso-
ciation studies have reported 133 loci to be associated with UC,
many of which are associated with defects in the immune sys-
tem. Current knowledge supports that UC is caused by an inap-
propriate immune response to the commensal microorganisms
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living in the gastrointestinal tract, collectively termed the gut
microbiota.5–10
Ulcerative colitis is characterized by superﬁcial inﬂamma-
tory changes limited to the mucosa and submucosa of the colon.5
Markers of inﬂammation obtainable in feces or serum include C-
reactive protein in serum and the proteins lactotransferrin and
calprotectin in feces.11,12 C-reactive protein may be increased dur-
ing the active phase of UC and is mainly produced in the liver in
response to stimulation by proinﬂammatory mediators produced
at the site of inﬂammation. Lactotransferrin is involved in the
mucosal innate immune system response. It is an iron-binding
glycoprotein with antimicrobial properties and is expressed by
activated neutrophils and is released by the injured tissue.13,14
Calprotectin is a complex between the 2 proteins S100-A8 and
S100-A9 and is involved in the recruitment of leukocytes. Addi-
tionally, calprotectin has antimicrobial activity toward bacteria
and fungi and composes up to 60% of the soluble cytosol proteins
in human neutrophils.15,16 Increased abundance of fecal calprotec-
tin is a sensitive marker for intestinal inﬂammation but has also
been seen with the use of nonsteroidal anti-inﬂammatory drugs
and increasing age.14 The abundance of all 3 proteins increases in
response to intestinal inﬂammation.
Accordingly, diagnostic and prognostic markers for IBD,
which would be valuable tools that could signiﬁcantly improve
treatment outcome, are currently missing. In this project, we
investigate protein changes in the intestinal tissue, in contrast to
proteins released to the bloodstream or feces. The aim was to
increase our knowledge of the UC etiology and to identify
markers, which could be translated to clinical use. Several studies
have investigated protein changes in the colon mucosa tissue.
However, so far mainly gel-based techniques have been used
where the proteins are separating based on mass and charge
(isoelectric point). Subsequently, the proteins are stained and
quantiﬁed, and up to hundreds of protein spots on the gel can be
identiﬁed by mass spectrometry (MS).11 One such study com-
pared colonic biopsies from 4 patients with UC and 5 controls
and identiﬁed 19 proteins with different abundance between the 2
groups, indicating that mitochondrial dysfunction might be
involved in the UC etiology.17 A more recent study compared
inﬂamed and noninﬂamed colon biopsies from 20 patients with
UC and identiﬁed 43 proteins that differentiated between the 2
conditions, many of which were involved in energy metabolism
and oxidative stress.18 The 2-dimensional gel-based techniques
allow for visual identiﬁcation of regulated proteins and protein
products that differ between different samples by image analysis
followed by MS protein identiﬁcation. However, 2-dimensional
gel-based techniques are laborious and are limited to the identiﬁ-
cation of protein spots in the hundreds. The identiﬁcation of non-
changing proteins is for that reason often omitted from the
analysis.11,19
In a recent study of patients with UC by Han et al,20 a gel-
free liquid chromatography (LC)-MS technique is used to analyze
protein changes in colonic biopsies, which led to the identiﬁcation
of 339 proteins.20 Several of the proteins were involved in inﬂam-
mation and cytoskeleton rearrangement. However, based on the
number of visualized protein spots from the gel-based studies, we
can expect the colonic biopsies to contain different proteins in the
thousands. The gel-free LC-MS study has, therefore, merely iden-
tiﬁed a fraction of the proteins, and high-throughput proteomics
technologies can be used to further identify and quantify disease-
speciﬁc proteins.11 We performed a proteomics study of morpho-
logically normal intestinal tissue from patients with UC, and we
found it important to use a current state-of-the-art proteomics
platform for high-throughput protein identiﬁcation and quantita-
tion in the colon mucosa.
MATERIALS AND METHODS
Study Cohort
The study cohort size was determined based on a power
analysis. Initially, we assumed that approximately 6000 t tests
were to be performed in the study with an effect chance of
0.01. Based on this, 10 subjects in each group to be compared
yields an estimated power of 95% to detect an effect size of 2.5
when correlating with Benjamini and Hochberg.21 Therefore, 10
patients with UC for whom endoscopy was planned and 10
healthy subjects were recruited at the outpatients clinic, Diagnos-
tic center Regional Hospital Silkeborg in the period from 2012 to
2013. Diagnosis of UC was based on standard clinical, endo-
scopic, and histological criteria, and an infectious etiology was
excluded.22 Information on diagnosis, medication, most recent
fecal calprotectin measurement, and smoking habits was recorded
from the patient records.
Written informed consent was obtained from all partic-
ipants before participation in the study, and the project was
approved by The Regional Scientiﬁc Ethical Committee
(S-20120204) and the Danish Data Protection Agency (2008-
58-035).
Samples Collection
Biopsies for the histological evaluation of disease severity
were sampled from descending colon, sigmoid colon, and rectum.
Three biopsies were taken from each location. The biopsies were
immediately placed on mixed cellulose ester ﬁlters (Advantec,
Japan), ﬁxed in phosphate-buffered 4% formaldehyde, and stored
at room temperature until tissue sample preparation 24 hours later.
Colon mucosal biopsies for MS were sampled 40 cm from the
anus by sigmoidoscopy. Patient biopsies were taken from
macroscopically normal tissue, and all controls had normal
ﬁndings at sigmoidoscopy. The biopsies were immediately trans-
ferred to cryotubes and snap-frozen in liquid nitrogen followed by
storage at 21408C until proteomics sample preparation.
Sample Preparation for Histology
The formalin-ﬁxated biopsies were parafﬁn embedded,
sliced in 10 mm, deparafﬁnized with tissue clear (Sakura, AJ
Alphen aan den Rijn, The Netherlands), and stained with
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hematoxylin and eosin (H&E) (Sigma-Aldrich, St. Louis, MO)23
or incubated with 2 mM TO-PRO-3 (Thermo Scientiﬁc, Waltham,
MA) in phosphate-buffered saline for 30 minutes, washed 3 times
in phosphate-buffered saline, and mounted.
The H&E-stained slices were investigated with
a DM5500B microscopy (Leica Camera, Solms, Germany) equip-
ped with PL Floutar ·16/0.5, and ·40/1.00 objectives and Retiga
2000R CCD Camera (Qimaging, Canada), and the TO-PRO-3
microscopy was performed on a SP5 confocal microscope (Leica
Camera) with a PL Floutar ·16/0.5, HCX PL APO ·63/1.40, and
HCX PL APO ·100/1.47 objectives. The pictures were processed
with ImageJ with the LOCI Tools plugin.24
Colon Inﬂammation Grade Score
As part of the routine patient care at Regional Hospital
Silkeborg, pathologists performed histological descriptions of
formalin-ﬁxed parafﬁn-embedded H&E-stained biopsies from de-
scending colon, sigmoid colon, and rectum. The biopsies were
characterized and assigned a colon inﬂammation grade score
(0 ¼ no disease activity, 1 ¼ light activity, 2 ¼ moderate activity,
and 3 ¼ severe activity) based on the histological descriptions
(Table 1).18,25 The sum of scores from the descending colon,
sigmoid colon, and rectum were squared to yield patient colon
inﬂammation grade scores. The scores were compared with the
relative abundance of known inﬂammatory proteins in the tissue,
and Pearson’s correlation coefﬁcients were calculated. The histo-
logical evaluation was supervised by a specialist in human pathol-
ogy, blinded for the result of the proteomic analyses.
Sample Preparation for Proteomics
The intestinal biopsies and lysates were kept on ice when
possible. Each biopsy was homogenized with steel beads in
0.5 mL of cold lysis buffer (5% sodium deoxycholate, 50 mM
triethylammonium bicarbonate, pH 8.5), using intense shaking on
a Precellys 24 homogenizer (Berting Technologies, Rockville,
MD). The protein concentrations of the lysates were estimated by
measuring absorbance at 280 nm (A280) using a NanoDrop 1000
UV-Vis spectrophotometer (Thermo Scientiﬁc). To increase the
accuracy of the A280 estimations, the concentration of 4 biopsy
lysates were determined using a bicinchoninic acid assay with
bovine serum albumin as standard, measured using an Inﬁnite
microplate reader (Tecan, Männedorf, Switzerland). All A280
measurements were postprocessing calibrated using the bicincho-
ninic acid assay protein determinations.
Protein digestion was performed using a modiﬁed ﬁlter-aided
sample preparation protocol.26–28 A biopsy lysate volume corre-
sponding to 100 mg of total solubilized protein was prepared for
LC-MS analysis for each biopsy. Proteins were reduced for 30 mi-
nutes at room temperature by adding tris(2-carboxyethyl)phosphine
(Thermo Scientiﬁc) to a ﬁnal concentration of 10 mM. The reduced
protein solution was transferred to a 30-kDa molecular weight
cutoff spin-ﬁlter (Millipore, Billerica, MA), and buffer exchange
was facilitated between all steps by centrifugation at 15,000g for
15 minutes at 48C. The proteins were alkylated using 100 mL of
50 mM 2-iodoacetamide (Sigma-Aldrich) in lysis buffer. Two
micrograms of sequencing grade modiﬁed trypsin (Promega,
Madison, WI) dissolved in 50 mL of digestion buffer (0.5% sodium
deoxycholate, 50 mM triethylammonium bicarbonate, pH 8.5) was
added to the spin-ﬁlter, and the proteins were digested to peptides
overnight at 378C. The peptide material was eluted from the spin-
ﬁlter and puriﬁed by phase inversions. One milliliter of ethyl ace-
tate with 1% formic acid was added to the peptide material, the tube
was vortexed, centrifuged at 15,000g for 5 minutes to obtain phase
separation, and the aqueous phase with peptides was recovered.26,29
The ﬁnal peptide eluent was dried down in a vacuum centrifuge
overnight and stored at 2808C until time of analysis.
TABLE 1. Disease Activity of Patients with UC
Patient





Time Difference (d) Year of DiagnosisDescendens Sigmoideum Rectum
UC_1 2 2 2 36 1285 7 2008
UC_2 0 0 1 1 889 20 2010
UC_3 1 2 2 25 1343 0 2003
UC_4 0 0 1 1 .3600 0 2010
UC_5 0 0 0 0 ,30 28 2009
UC_6 0 2 0 4 705 0 2006
UC_7 2 1 3 36 575 117 2008
UC_8 0 2 0 4 163 37 2011
UC_9 2 0 0 4 ,30 4 2000
UC_10 2 1 1.5 20.25 2060 5 2010
The histological grading of biopsies from colon descendens, colon sigmoideum, and rectum is used to calculate the colon inﬂammation grade score. Colon inﬂammation grade score ¼
(descendens score + sigmoideum score + rectum score)2. Additionally, the measured fecal calprotectin (F-Cal) and the time difference between the measured F-Cal and the biopsy
extraction are given.
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Proteomics—Analysis
Before LC-MS analysis, the dry peptide product was
reconstituted in 20 mL of 2% acetonitrile and 0.1% formic acid.
Five micrograms of peptide material as determined by A280
was analyzed per LC-MS analysis. All biopsies were analyzed
in triplicates and in a random order of biopsy analysis.30
The peptides were analyzed by LC-MS using an
UltiMate 3000 UPLC system (Thermo Scientiﬁc) coupled
online to a Q Exactive mass spectrometer (Thermo Scientiﬁc)
using a trapping column setup. The peptide material was
loaded onto a 2-cm trap column packed with Acclaim
PepMap100 C18, 5 mm 100 Å material (Thermo Scientiﬁc).
Subsequently, the peptides were separated using a 50-cm ana-
lytical column packed with Acclaim PepMap100 C18, 2 mm
100 Å material (Thermo Scientiﬁc). The peptides were eluted
from the column with a gradient of 96% solvent A (0.1%
formic acid) and 4% solvent B (0.1% formic acid in acetoni-
trile), which was increased to 8% solvent B on a 5-minute
ramp gradient and subsequently to 30% solvent B on a 225-
minute ramp gradient, with a constant ﬂow rate of 300 nL/min.
The column was washed with 90% solvent B for 10 minutes
and equilibrated for 40 minutes, resulting in a total analysis
time of 290 minutes per LC-MS analysis. Both columns were
kept at 408C. The eluting peptides were introduced directly
into the mass spectrometer by a picotip emitter for nanoﬂow
ionization (New Objective, Woburn, MA). The mass spec-
trometer was operated in positive mode using a data-
dependent acquisition method. A full MS scan in the mass
range of m/z 400 to 1200 was acquired at a resolution of
70,000. In each cycle, the mass spectrometer would trigger
up to 12 MS/MS acquisitions of eluting ions based on highest
signal intensity for fragmentation. The MS/MS scans were
acquired with a dynamic mass range at a resolution of 17,500.
The precursor ions were isolated using a quadrupole isolation win-
dow of 1.6 m/z and fragmented using high-energy collision with
a normalized collision energy of 27. Fragmented ions were dynam-
ically added to an exclusion list for 30 seconds.
Proteomics—Raw File Analysis
The measured peptide signal intensities from the full MS
scan were integrated using MaxQuant 1.4.1.2 software31,32 and
used to calculate the relative protein quantities (label-free
quantitation). The fragment scans were searched against a Uni-
prot database containing all reviewed Homo sapiens proteins
(downloaded October, 8, 2013, containing 20,277 entries).
The following abundant peptide modiﬁcations were included
in the analysis: carbamidomethylated cysteine residues (ﬁxed),
acetylation of N peptides from the N-terminal of proteins (var-
iable), oxidation of methionine (variable), and deamidation of
asparginine and glutamine residues (variable).33,34
Proteomics—Protein Data Processing
A target-decoy fragment spectra search strategy was
applied and used to adjust the false discovery rate of identiﬁed
peptides and proteins to below 1% false discovery rate. For
quantiﬁed proteins, additional ﬁltering of the protein and
peptide data was done to ensure high-quality quantitative data:
(1) The quantitation of any protein was required to be based on
at least 2 sequence-unique quantiﬁable peptides. (2) The
sequence-unique peptides were required to be quantiﬁable in
at least half of the UC biopsies or the control biopsies. (3) All
biopsies had been analyzed in triplicates on the LC-MS
system. To remove replicate analyses with poor repeatability,
all measured protein abundances were log2 transformed and
the repeated analyses were investigated individually for the
biopsies by scatter plots. Ideally, the repeated analysis of
a biopsy should yield identical protein abundances, repre-
sented by a Pearson’s correlation coefﬁcient of 1 in the scatter
plots, indicating a perfect correlation. Individual replicate
analyses with a Pearson’s correlation less than 0.95 were
removed from further analysis, to ensure that only highly
reproducible replicates were included in the ﬁnal data set.
(4) To further identify replicate outliers, a principle compo-
nent analysis (PCA) was performed in Perseus v1.4.1.3. The
input for the PCA was all measured protein abundances in all
replicates. For the purpose of conducting PCA, missing values
(i.e., proteins where a quantitation value was not obtained for
a given replicate analysis) were replaced with values from
a normal distribution (width 0.3 and down shift 1.8) to simu-
late signals from low abundant proteins.35 The grouping of the
replicates on the calculated scores plots was investigated.
Gene ontology annotations were imported from Uniprot
Knowledgebase for all quantiﬁed proteins using STRAP
v1.5 to classify the proteins.36
Proteomics—Statistical Analysis
The repeated measurements of protein abundances were
combined in Perseus v1.4.1.3 by taking the median biopsy wise,
and the biopsies were grouped according to disease state: 10
biopsies from patients with UC and 10 from controls. To identify
proteins with a statistically signiﬁcant mean abundance change
between the UC group and the control group, 2-sided t tests were
performed. As several thousand t tests were performed, we
applied permutation-based false-positive control to correct for
multiple hypothesis testing (parameters: s0 ¼ 1, 250 randomiza-
tions).37–39 Up to 15% of the statistically signiﬁcantly changing
proteins were allowed to be false positives (i.e., the measured
average protein abundance is not statistically signiﬁcantly differ-
ent between the UC group and the control group) to ensure suf-
ﬁcient input for the downstream protein functional analysis.37
Proteins displaying a statistically signiﬁcant mean abundance
change were further investigated using SPSS statistics v22
(IBM, Armonk, NY). The MS data have been deposited to the
ProteomeXchange Consortium (http://proteomecentral.proteo-
mexchange.org) by means of the PRIDE partner repository with
the data set identiﬁer PXD001608.40,41




The recorded medical information (Table 2) revealed 9 pa-
tients receiving 5-aminosalicylic acid, 2 patients receiving azathio-
prine, and 1 patient receiving glucocorticoid treatment, whereas 1
control received insulin treatment. The study cohort age, gender,
and current smoking status was not found to be statistically differ-
ent between the patients with UC and controls. However, the num-
ber of former smokers was increased in the UC group.
Histological Analysis
To assess cell density and tissue morphology in the
extracted biopsies, we investigated the H&E-stained sections by
light microscopy (Fig. 1). The crypt architecture was preserved in
all control samples and all UC biopsies. However, we observed an
increased number of stained cell nuclei between the intestinal
crypts in the biopsies from patients with UC compared with con-
trols. The majority of cells between the intestinal crypts had seg-
mented cell nucleus, a characteristic of polymorphonuclear
neutrophils (PMNs).42,43 As the biopsies for the proteome analysis
were obtained in parallel, we expect these biopsies to have the
same characteristics.
Proteomics Veriﬁcation
Before homogenization of the biopsies for proteomics
sample preparation, the average wet weight of the biopsies was
measured to be 4.9 mg (3.6–5.9 mg; 25th–75th percentiles). Fol-
lowing homogenization of the biopsies in lysis buffer, the protein
concentration of the lysate was measured and the average ex-
tracted protein yield, calculated from the biopsy wet weight,
was 10% (9%–11%; 25th–75th percentiles), indicating an efﬁ-
cient and reproducible homogenization.
The proteins in each homogenized sample were digested to
peptides using the ﬁlter-aided sample preparation protocol, and
the complex peptide material was analyzed by LC-MS/MS with
label-free quantitation.31,32 During the 290-minute analysis of
each homogenized and digested sample, the MS system detected
peptide elusion from the LC column and selected up to 12 pre-
cursor ions per MS cycle for fragmentation (Fig. 2). By bioinfor-
matics analysis, the proteins were subsequently identiﬁed and
quantiﬁed. To investigate the repeatability of the LC-MS analysis,
TABLE 2. Study Cohort Information and Analysis
ID Age Gender Smoking Smoking History Medicine (per day)
UC_1 27 Male Never Asacol (5-aminosalicylic acid) 1600 + 800 + 1600 mg
UC_2 45 Male Stopped 2009 Asacol (5-aminosalicylic acid) 1600 mg · 2
Asacol (5-aminosalicylic acid) suppository 500 mg
UC_3 44 Male Stopped 2000 Imurel (azathioprine) 150 mg · 1
UC_4 45 Female Stopped 2005 Pentasa (5-aminosalicylic acid) suppository 1 g
UC_5 26 Female 10 cigarettes per day Current Mesasal (5-aminosalicylic acid) suppository 500 mg
UC_6 70 Female Stopped 1998 Mesasal (5-aminosalicylic acid) suppository 500 mg
UC_7 62 Male Stopped 2009 Imurel (Azathioprin) 100 mg; Pentasa (5-aminosalicylic acid) 2000 mg
UC_8 36 Male Never Asacol (5-aminosalicylic acid) 1600 mg · 2
Asacol (5-aminosalicylic acid) suppository 500 mg
UC_9 68 Female 10 cigarettes per day Current Asacol (5-aminosalicylic acid) 1600 mg · 2
UC_10 22 Female Never Asacol (5-aminosalicylic acid) 1600 mg · 2
Asacol (5-aminosalicylic acid) suppository 500 mg
Pred-Clysma (glucocorticoid) 24 mg
Ctrl_1 54 Male Never
Ctrl_2 27 Male Never NovoRapid (insulin)
Ctrl_3 42 Male Never
Ctrl_4 48 Male Never
Ctrl_5 54 Female Stopped 1992
Ctrl_6 27 Female Stopped 2011
Ctrl_7 42 Female Never
Ctrl_8 23 Male Never
Ctrl_9 28 Male Never
Ctrl_10 31 Male Stopped 2008
Age and gender were not found to be statistically signiﬁcantly different (P . 0.05) between the patients with UC (n ¼ 10) and the controls (n ¼ 10) as determined by 2-sided t tests.
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the technical triplicate analyses of each biopsy were analyzed by
scatter plots, plotting the abundance of each quantiﬁed protein in
one replicate against the same protein abundance as determined in
other replicates, biopsy wise. Ideally, the repeated analysis should
yield identical protein abundances, represented by a Pearson’s
correlation coefﬁcient of 1 (Fig. 3A). Of the 60 LC-MS analyses,
only 1 replicate from UC_4 and 1 from UC_5 had coefﬁcients less
than 0.95 and the 2 outlying replicates were removed from further
analysis. The result demonstrates a high degree of technical
repeatability of the method, that is, a low variance of the measured
protein abundances when the same biopsy is analyzed repeatedly.
To investigate how the measured protein abundances varied
between all replicates and identify which replicates yielded sim-
ilar protein abundances, a PCA was performed. A PCA is a sta-
tistical analysis technique that allows for reducing a large number
of variables to a smaller number of groups (principle compo-
nents), which can be visualized on scores plots and used to
interpret the variance in a complex data set, like that of
high-throughput proteomics.44 All measured protein abundances
in all LC-MS analyses were used as input for the PCA, and 2-
dimensional scores plots were constructed (Fig. 3B). The scores
plot describes how the replicates group relative to one another,
based on the differences in measured abundances of all proteins.
In effect, replicates where similar protein abundances have been
measured will be close in space on the scores plot, relative to the
other replicates, and the PCA scores plot can thus be used to
identify outliers. The PCA, thereby, includes the variance
between all biopsies, unlike the scatter plots that only take the
variance in the repeated analysis of the individual biopsies into
account. Principal component 1 and principle component 2 rep-
resent the largest and second largest variance in the protein abun-
dance data set, respectively, and explain 35.4% of the variance in
the protein abundance data set. In all cases, the scores plot sepa-
rates all biopsies from one another, in contrast to the repeated
triplicate analysis of each biopsies, which group together for each
individual biopsy (Fig. 3B, circles). This indicates that the mea-
sured protein abundances are more similar when the same biopsy
is analyzed repeatedly than when different biopsies are analyzed.
The variance in protein abundances between the different biop-
sies, therefore, is larger than the technical variance when the same
biopsy is analyzed repeatedly, as expected for sensitive methods
that validate the methodology.
Proteomics—Data Analysis
Applying our strict criteria, 5711 quantiﬁable proteins
remained postﬁltering. The quantiﬁable proteins were classiﬁed
by biological function, subcellular location, and molecular
function, using available data from Uniprot Knowledgebase and
gene ontology database (Fig. 4). The analysis of the biological
processes performed by the proteins revealed that 68% of the
quantiﬁed proteins were involved in cellular processes, such as
intracellular communication; 55% of the proteins were involved
in modulation of the frequency, rate, or extent of any biological
process, quality, or function; and 29% were involved in metabolic
processes, which include anabolism and catabolism by which
living organisms transform chemical substances. We next inves-
tigated the cellular component of the proteins, that is, which parts
of a cell or its extracellular environment the protein has been
reported to be present. A somewhat even distribution was found
between proteins associated with the cell cytoplasm, the cell
nucleus, and the extracellular environment of the cell with 48%,
42%, and 35%, respectively. Finally, we investigated which pri-
mary molecular functions the proteins took part of. The analysis
revealed that 68% of the proteins were involved in selective, non-
covalent binding with other molecules, and 41% were involved in
biologically catalyzed reactions. Based on the protein classiﬁca-
tion analysis, the quantiﬁed proteins originate from all cellular
compartments, indicating that no systematic loss of proteins has
occurred using the protocol and thus an unbiased analysis.
FIGURE 1. Biopsy histology analysis. A, Overview of the human small
and large intestine. B, Cross section of a human colon. Representative
H&E-stained colon biopsy slices from (C) control Ctrl_10 and (D)
patient UC_05. The crypt architecture is in both slices preserved.
However, an increased number of stained cell nuclei surrounding the
crypts (red arrows) are apparent in the UC biopsies compared with the
control biopsies (scale bars 100 mm).
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Next, we analyzed the quantitative information obtained
about the proteins in each biopsy. The measured protein
abundances in the biopsies from the patient with UC were
compared with the abundances in the biopsies from the control
group, and t tests were performed to identify proteins with a sta-
tistically signiﬁcant mean abundance change between the 2
groups. Forty-six proteins demonstrated a statistical signiﬁcant
mean abundance change between the UC biopsies and the control
biopsies. All the 46 proteins were measured with an abundance
that, on average, was different between the UC biopsies and con-
trol biopsies by a factor of 2.8 or more, which is referred to as the
fold change. Of the 46 proteins, 33 proteins were more abundant
in the UC biopsies and 13 proteins were less abundant (Table 3).
The protein with the largest mean fold abundance change between
the UC and control biopsies was lactotransferrin, which was 219
times more abundant in the UC group. To further validate the
measured protein abundances, we correlated the relative abun-
dance of lactotransferrin and calprotectin with the severity of
FIGURE 2. Representative 2-dimensional plot of the liquid chromatography-mass spectrometry analysis of patient UC_9 illustrating the complexity
of the analyzed peptide material. On the x-axis, the intensities of the peptide ion signals of the 19,549 acquired full MS scans are plotted, with
a color gradient from white to green. The time of analysis is given on the y-axis. Each full MS scan was succeeded by up to 12 MS/MS scans of ions
detected on the full MS scan and each cycle time was approximately 1 second; + indicates that the given ion signal was selected for MS/MS
analysis, which came to 119,560 MS/MS scans in this 1 replicate.
FIGURE 3. Proteomics data veriﬁcation. A, Representative scatter plot of the triplicate biopsy analysis of UC_1 of the 5711 quantiﬁed proteins. The
log2 transformed protein abundances of all proteins in replicates 1, 2, and 3 are plotted against one another on the x- and y-axes, respectively.
Ideally, the measurements should yield identical protein abundances, represented by a Pearson’s correlation coefﬁcients (R) of 1. B, PCA scores
plot of principle components 1 and 2 of the protein abundances as measured in the UC replicates (+) and control replicates (h). Technical
replicates (encircled) group together in all cases, demonstrating a high degree of technical repeatability of the method. The study cohort subject
ID is given as numbers (e.g., red 3 at [+] equals UC_3) (Table 2).
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tissue inﬂammation in the patients with UC, as determined by
histology. Both proteins are used to monitor UC disease activity.11
Biopsies from descending colon, sigmoid colon, and rectum were
assigned a colon inﬂammation grade score based on histology
descriptions (Table 1). A good correlation was found between
the colon inﬂammation grade scores and the relative abundance
of calprotectin and lactotransferrin in the tissue, with Pearson’s
correlation coefﬁcients of 0.84 and 0.91 for S100-A8 and
S100-A9 protein, respectively, and 0.82 for lactotransferrin
(Fig. 5). Finally, we correlated the relative abundance of calpro-
tectin in the tissue to the most recent measure of fecal calprotectin
as determined by routine tests. However, no correlation could be
found, and a Pearson’s correlation coefﬁcient of 0.33 was calcu-
lated (data not shown).
Eleven of the 46 proteins with statistically signiﬁcantly
altered abundance in the UC biopsies are present in neutrophils
and have been associated with the formation of neutrophil
extracellular traps (NETs) (Table 3, asterisk indicates protein
names).45 NETs are a method of action by PMNs and are com-
posed of extracellular ﬁbrillar networks mainly of relaxed DNA
and also contain proteins and other effector molecules, some of
which have antimicrobial and antibody-like properties. NETs are
released from PMNs in response to inﬂammatory stimuli, trap-
ping the invading microorganisms, and facilitates interaction
with other effector molecules that kill the microorganisms.45–47
All 11 NET-associated proteins were found with increased abun-
dance in the UC biopsies, and on average, the proteins were 42.2
times (P , 0.0005) more abundant in the UC biopsies (Fig. 6).
Confocal Laser Scanning Microscopy
To investigate if the increased abundance of PMN-
associated proteins was a result of an increased abundance of
PMNs, and if the PMNs were intact or found as NETs, we
investigated the TO-PRO-3 DNA–stained biopsy sections by con-
focal microscopy. The increased density of cell nuclei observed
on the H&E-stained sections was again observed (Fig. 7), as was
the segmented multilobulated nuclei, a characteristic of PMNs
(Fig. 8A).42 The PMNs were observed abundantly in biopsies
from the UC group and occasionally in the control group. In
addition to intact PMNs, we observed neutrophils that had
excreted nuclear DNA into the extracellular environment forming
NETs at 2 distinct locations in biopsies from UC_4 (Fig. 8B).43
DISCUSSION
The main result of this study is the identiﬁcation of several
novel proteins, which are present in increased abundance in the
UC colonic tissue. Eleven of the proteins were associated with
neutrophils and NETs, and the increased presence of both in the
UC colonic tissue was veriﬁed with light microscopy and
confocal microscopy.
Several studies have successfully analyzed different aspects
of UC using genomic and transcriptomic techniques. However,
sequencing techniques do not directly yield information about the
abundance of the end product: the proteins, which are a combi-
nation of the newly synthesized and the degraded protein.11 In our
proteome analysis of colon mucosa biopsies from 10 patients with
UC and 10 controls, we were able to quantify 5711 proteins in the
colon mucosa biopsies, and the data quality was ensured by scat-
ter plots and PCA. In previous studies, the amounts of calprotectin
and lactotransferrin in feces have been found to correlate well
with the degree of neutrophil inﬁltration and inﬂammation of
the intestine.11,15 We found that the abundance of these proteins
in the colonic tissue correlated well with the colon inﬂammation
grade scores, providing validation to the proteomics protein abun-
dance data and the methodology. However, we found that the
FIGURE 4. Gene ontology characterization of the 5711 quantiﬁed proteins in terms of (A) biological processes performed by the proteins, (B)
cellular component to which the proteins are associated, and (C) the primary molecular functions of the proteins.
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TABLE 3. List of the 46 Proteins with a Statistically Signiﬁcant Mean Abundance Change Between the UC Biopsies and Controls
Fold
Change Uniprot Acc. Protein Name Protein Function
Peptides (Unique),
Seq. Cov. MW pI
219.2 P02788 Lactotransferrin* Iron-binding protein with antimicrobial properties include bacteriostasis 51 (49), 72.7% 76,165 8.47
92.1 P14780 Matrix metalloproteinase-9* Proteolysis of the extracellular matrix and leukocyte migration 30 (30), 51.8% 66,609 5.44
63.3 P05164 Myeloperoxidase* Part of the defense system of PMN; responsible for microbicidal activity
against a wide range of organisms
48 (41), 59.2% 66,107 9.22
31.4 P24158 Myeloblastin PMN protease; degrades elastin, ﬁbronectin, laminin, vitronectin, and collagen 7 (7), 36.3% 24,247 7.79
31.3 P08246 Neutrophil elastase* Modiﬁes functions of natural killer cells, monocytes, and granulocytes 11 (11), 54.7% 25,561 9.89
18.0 Q9NRD8 Dual oxidase 2 Lactoperoxidase-mediated antimicrobial defense at the surface of mucosa 42 (42), 33.6% 172,843 7.92
16.7 P11215 Integrin alpha-M Adhesive interactions of monocytes, macrophages, and granulocytes 34 (33), 37.7% 125,471 6.75
16.3 P06702 Protein S100-A9* One of the subunits in calprotectin; regulates inﬂammatory processes and
immune response; Induce neutrophil chemotaxis, adhesion, increase
bactericidal activity and degranulation
10 (10), 78.9% 13,110 5.71
13.7 P80188 Neutrophil gelatinase-associated
lipocalin
Apoptosis, innate immunity, and renal development 12 (12), 63.6% 20,547 9.02
11.8 P80511 Protein S100-A12* Regulates inﬂammatory processes and immune responses; recruitment of
leukocytes, promotion of cytokine and chemokine production, and
regulation of leukocyte adhesion and migration; antifungal and
antimicrobial activity
5 (5), 35.9% 10,443 5.80
10.6 P22894 Neutrophil collagenase Degrade ﬁbrillar collagens 14 (14), 37.7% 41,937 5.49
9.9 P59666 Neutrophil defensin 3* Fungicide, antiviral, and antimicrobial activity against bacteria 5 (5), 26.6% 3,492 8.33
9.4 P08637 Low-afﬁnity immunoglobulin
gamma Fc region receptor
III-A
Binds monomeric, complexed, or aggregated IgG; mediates antibody-
dependent responses (e.g., phagocytosis)
2 (2), 8.3% 27,324 8.24
9.2 P52790 Hexokinase-3 Metabolic processes; phosphorylation of hexoses 21 (18), 31.3% 99,025 5.23
8.7 O75594 Peptidoglycan recognition
protein 1
Innate immunity; has bactericidal activity 5 (5), 41.3% 19,434 8.23
8.5 P36222 Chitinase-3-like protein 1 Regulates inﬂammatory cell apoptosis, dendritic cell accumulation, and
macrophage differentiation; facilitates invasion of pathogenic enteric
bacteria into colonic mucosa
14 (14), 44.9% 40,488 8.64
7.8 Q06141 Regenerating islet-derived
protein 3-alpha
Antimicrobial activity against gram-positive bacteria 4 (4), 36.6% 16,566 7.83
7.3 Q1HG44 Dual oxidase maturation factor 2 Required for dual oxidase 2 maturation and transport to the plasma membrane 4 (4), 16.9% 34,786 8.51
6.6 Q05315 Galectin-10* Regulates immune responses; recognition of cell surface glycans 11 (11), 67.6% 16,321 6.80
6.6 P35228 Nitric oxide synthase, inducible Produces tumoricidal and bactericidal nitric oxide in macrophages 42 (41), 45.4% 131,117 8.20
6.2 P16050 Arachidonate 15-lipoxygenase Regulates macrophage function and epithelial wound healing in the cornea;
may favor clearance of apoptotic cells during inﬂammation
25 (25), 52.1% 74,673 6.14
5.9 P12724 Eosinophil cationic protein* Antibacterial activity, including cytoplasmic membrane depolarization 10 (10), 46.9% 15,518 10.47
5.7 Q8IX19 Mast cell-expressed membrane
protein 1



























TABLE 3 (Continued )
Fold
Change Uniprot Acc. Protein Name Protein Function
Peptides (Unique),
Seq. Cov. MW pI
5.1 P10153 Nonsecretory ribonuclease Pyrimidine-speciﬁc nuclease; selective chemotactic for dendritic cells 8 (8), 44.1% 15,463 9.20
5.0 P11678 Eosinophil peroxidase Mediates tyrosine nitration of secondary granule proteins in mature eosinophils 51 (44), 56.8% 81,040 10.70
4.5 P41218 Myeloid cell nuclear differentiation
antigen*
Plays a role in the granulocyte/monocyte response to interferon 17 (17), 39.1% 45,836 9.76
4.4 P06310 Ig kappa chain V-II region RPMI
6410




Neutrophil chemotaxis; may function downstream of heterotrimeric G proteins
in neutrophils
8 (8), 6.4% 186,203 6.03
4.0 P01040 Cystatin-A Intracellular thiol proteinase inhibitor; desmosome-mediated cell–cell adhesion
in the lower epidermis levels
2 (2), 30.6% 10,875 5.39
4.0 Q96Q80 Derlin-3 Functional component of endoplasmic reticulum-associated degradation for
misfolded lumenal glycoproteins
4 (3), 26.8% 26,678 8.64
3.9 Q7Z7N9 Transmembrane protein 179B Integral component of membrane 2 (2), 8.2% 23,550 8.10
3.8 Q70J99 Protein unc-13 homolog D Regulates secretory lysosome exocytosis in mast cells and cytotoxic granule
exocytosis in lymphocytes; required for granule maturation and docking
16 (16), 24.7% 123,281 6.19
3.5 P08311 Cathepsin G* Serine protease; cleaves complement C3; has antibacterial activity against the
gram-negative bacterium Pseudomonas aeruginosa
16 (16), 54.1% 26,757 11.37
0.4 P29966 Myristoylated alanine-rich
C-kinase substrate
Filamentous actin cross-linking protein; binds calmodulin, actin, and synapsin 11 (11), 49.1% 31,423 4.46
0.3 P00326 Alcohol dehydrogenase 1C Oxidation of alcohol 27 (10), 64.8% 39,868 8.63
0.3 P20039 HLA class II histocompatibility
antigen, DRB1-11 beta chain
Binds peptides derived from antigens that access the endocytic route of
antigen-presenting cells and presents them on the cell surface for
recognition
9 (2), 40.6% 27,230 6.49
0.3 P10082 Peptide YY Gut peptide; inhibits exocrine pancreatic secretion, and jejunal and colonic
mobility; has vasoconstrictory action
3 (3), 29.9% 4,410 8.34
0.3 Q12805 EGF-containing ﬁbulin-like
extracellular matrix protein 1
May play a role in cell adhesion and migration; binds the EGF receptor,
inducing phosphorylation and activation
15 (15), 43.0% 52,765 4.85
0.3 Q9HBI6 Phylloquinone omega-hydroxylase
CYP4F11
Oxidizes a variety of compounds, including fatty acids and xenobiotics; may
play a role in blood coagulation
11 (3), 26.7% 60,146 6.26
0.3 P15502 Elastin Major structural protein of tissues; regulates proliferation and organization of
vascular smooth muscles
6 (6), 17.7% 65,721 10.32
0.3 P10915 Hyaluronan and proteoglycan link
protein 1
Stabilizes the aggregates of proteoglycan monomers with hyaluronic acid in
the extracellular cartilage matrix
14 (13), 48.6% 38,840 6.85
0.2 Q86Y39 NADH dehydrogenase
(ubiquinone) 1 alpha
subcomplex subunit 11
Subunit of the mitochondrial membrane respiratory chain NADH
dehydrogenase, thought not to be involved in catalysis






























amount of fecal calprotectin did not correlate with the colon
inﬂammation grade scores or the measured amount of calprotectin
in the tissue (data not shown), which have been reported by
others.48 A likely explanation is that the measure of fecal calpro-
tectin and the biopsy extraction was not conducted in parallel in
the present study, and only for 3 of the 10 patients with UC were
the fecal calprotectin measures obtained on the day. Additionally,
fecal calprotectin is a marker for inﬂammation in the entire intes-
tinal system, in contrast to the colon inﬂammation grade score and







































































































































































































































































































































































































































































































































































































































































FIGURE 5. Correlation analysis of inﬂammatory proteins. Colon
inﬂammation grade scores and the protein abundance in the colon
tissue of the inﬂammatory proteins lactotransferrin (d), S100-A8 (-),
and S100-A9 (:) (S100-A8 and S100-A9 protein constitute calpro-
tectin).
FIGURE 6. Fold change of statistically signiﬁcantly changing NET-
associated proteins between biopsies from the patients with UC and
controls. The 11 proteins are on average 42.2 times (P , 0.0005) more
abundant in the biopsies from the UC group compared with the
biopsies from the control group. Center line shows the median, box
limits indicate the 25th and 75th percentiles, whiskers extend 1.5
times the interquartile range from the 25th and 75th percentiles,
crosses represent sample means, and the circle represents the fold
change of lactotransferrin that lies outside the whiskers.
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ascending colon was not considered. This is likely why, for example,
patient UC_4 treated with suppository Pentasa had a colon inﬂam-
mation grade score of 1, indicating for the most part healthy looking
biopsies. However, .3600 mg of fecal calprotectin per gram stools
was measured indicating inﬂammation in the transverse colon or the
ascending colon, too far from the rectum for the treatment with sup-
pository Pentasa to have an effect. Finally, it has been reported that
fecal calprotectin can be increased 3 months before a disease ﬂare.49
As the patients in this study were not followed up after the biopsy was
taken, it cannot be excluded that these patients later could have devel-
oped disease ﬂares, which caused the elevated fecal calprotectin.
Of the 5711 quantiﬁable proteins, 46 proteins were
measured to have a statistically signiﬁcant change in abundance
between the biopsies from the patients with UC and the controls. Of
these, 33 proteins were more abundant in the UC biopsies. Several of
the proteins with a statistically signiﬁcant abundance increase were
involved in inﬂammation. On comparison with the only other gel-free
LC-MS study conducted, we found several proteins that were
determined to be more abundant in the UC colon tissue in both
studies, namely, Protein S100-A9 (calprotectin), neutrophil elastase,
myeloperoxidase, neutrophil defensin, and cathepsin G.20 These con-
sistent ﬁndings validate the study. However, the study by Han
et al20 additionally reported that a number of histones and ﬁbrinogen
proteins were more abundant. These proteins were identiﬁed and
quantiﬁed in the present study; however, we could not conﬁrm the
increased abundance. However, our study found several proteins
associated with the innate immune system to be increased in abun-
dance in the UC colonic tissue. The differences between ﬁndings in
the 2 studies are mainly ascribed to differences in the obtained patient
material and study design. The advantages of a state-of-the-art instru-
ment and bioinformatics platform are demonstrated in the increase
from up to 339 proteins in the study by Han et al20 to the 5711
quantiﬁable proteins in the present study, thus providing information
on the regulation of a great number of proteins and thus cellular
functions. A potential drawback of the high number of quantiﬁable
proteins is that a large number of t tests need to be performed during
the statistical analysis. To avoid a high number of false positives
among the proteins found to be statistically signiﬁcant, multiple
hypothesis testing must be applied, which increases the requirements
for the P-values.21 As a consequence, when many proteins are quan-
tiﬁed and analyzed, the statistical analysis results in the need for
a higher number of included subjects in the study. As an example,
an overabundance of the enzyme indoleamine-2,3-dioxygene has
been found in intestinal mucosal tissue from patients with IBD com-
pared with normal mucosa, hypothesizing an involvement of the
Kynurenine pathway of tryptophan metabolism in the IBDs.50,51
FIGURE 7. Confocal microscopic images of TO-PRO-3–stained biopsy slices (scale bars 100 mm): (A) Ctrl_5 and (B) UC_3. An increased number of
stained cell nuclei surrounding the intestinal crypts are in general apparent in the UC biopsies compared with the control biopsies.
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Indoleamine-2,3-dioxygenase is an intracellular enzyme that catalyzes
the production of Kynurenine from the amino acid tryptophan. The
enzyme is regulated by gamma-interferon of the immune system.52
The protein in our study was detected with a 1.8 mean fold abundance
increase in the UC biopsies compared with controls but not statistically
signiﬁcant. This indicates that a larger study cohort could have iden-
tiﬁed a higher number of statistically signiﬁcantly changed proteins.
Gel-free quantitative LC-MS studies hold a number of
advantages over 1- and 2-dimensional gel-based approaches, includ-
ing increased sensitivity, increased dynamic range, and identiﬁcation
and quantiﬁcation of proteins in the thousands instead of hundreds.
However, the gel-free approaches such as the present study are limited
in the ability to detect protein fragment products.11,19 The increased
sensitivity of the gel-free approaches becomes apparent when consid-
ering that the gel-free LC-MS method used in this study analyzed 5
mg of the ﬁnal material compared with the hundreds of microgram
material used for the 2-dimensional gel analysis, which allowed us to
conduct repeated analysis of each biopsy.17,53 Two-dimensional gel
studies are usually limited to proteins within a molecular mass range
of 15 to 200 kDa and isoelectric point of the proteins in the range of 3
to 10. These limitations do not apply for gel-free approaches, and
applying these criteria to the 46 proteins detected with a statistically
signiﬁcant change in this study 30.4% (14 proteins) would not be
detectable with 2-dimensional gel studies (Table 3).11,19 This in-
cludes protein S100-A12, which was found to be 11.8-fold
increased in the UC colonic tissue and also has been found ele-
vated in the serum of children with IBD.54 Interestingly, the pres-
ent study is the ﬁrst MS-driven proteomics study to measure an
increased abundance of lactotransferrin in the UC colonic tissue.
The increased abundance of fecal lactotransferrin is used as
a marker for inﬂammation, and the protein should have been
detectable using 2-dimensional gel-based analysis.11,55 However,
it is possible that the relative abundance of this protein remains
too low for gel-based studies. Nonetheless, the protein abundance
in the colonic tissue correlates well with the abundance of cal-
protectin in the tissue, and the colon inﬂammation grade scores in
this study, as expected.11,55 Another protein involved in inﬂam-
mation and found with increased abundance in the UC biopsies is
myeloblastin. Myeloblastin is a protease found in neutrophils and
was found to be 31.4-fold more abundant in the UC colonic
biopsies compared with controls. The protease has speciﬁcity
toward, among others, the protein elastin, which accordingly
has a decreased abundance in the UC biopsies, with a 1/3.3-
fold change. Another interesting protein found with 8.7-fold
increase in abundance in the UC colonic biopsies is peptidoglycan
recognition protein 1. The protein is part of the innate immune
FIGURE 8. Confocal microscopy images of TO-PRO-3–stained biopsy slices from the UC group (scale bars 100 mm): (A) UC_6 with an intact
neutrophil, with segmented multiobulated-shaped nucleus; (B) UC_4 with NET formation by excretion of the neutrophil DNA.
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systems recognition of microorganisms and mediates its effect by
binding bacterial peptidoglycans, which triggers a signaling cas-
cade.56,57 This is the ﬁrst study to ﬁnd an increased abundance of
peptidoglycan recognition protein 1 in UC colonic tissue.
Hexokinase-3 is an intracellular enzyme that phosphorylates glu-
cose into glucose-6-phosphate and, together with hexokinase 1, 2,
and 4, is a central rate-limiting step in glucose metabolism.58,59
Not much is known about the regulation of hexokinase 3; how-
ever, the 9.2-fold increased abundance of this enzyme in the UC
biopsies indicates that glucose metabolism might be increased in
the inﬂamed tissue compared with controls.
The increased abundance of inﬂammation-associated pro-
teins points to an activated innate immune system in the UC
colon, even in colonic tissue without visible inﬂammation. It
should be noted that we do not know the impact of the medication
on the protein regulations. However, as most of the statistically
signiﬁcant changed proteins are involved in inﬂammatory pro-
cesses, these protein changes are likely caused by the disease
development. Additionally, the number of former smokers was
increased in the UC group compared with controls. The impact of
cigarette smoking on the etiology of UC has been vastly debated
over the years.60–65 Current knowledge supports that the risk for
developing UC is highest 2 to 5 years after smoking cessation and
remains elevated for more than 20 years, and patients with UC are
more prone to disease ﬂairs if they quit smoking.60 However, the
subject is still debated and the dose–response effect remains to be
properly determined. Based on the present study, we cannot
assess the impact of former smoking on the protein data.
To evaluate the morphology of the tissue, the biopsies were
sectioned and H&E stained, and the histological evaluation was
done by light microscopy. The intestinal crypts were preserved in
all biopsies, in agreement with the biopsies being taken from
morphologically normal tissue. However, an increased abundance
of cell nuclei in the colon mucosal tissue was observed between
the intestinal crypts, with segmented cell nuclei, a characteristic of
PMNs. Based on the proteomics data and light microscopy, we
here verify the increased density of PMNs in the UC colonic
tissue. This has been reported by other groups as well, but this
is the ﬁrst study to support the light microscopy identiﬁcation of
the PMNs with MS techniques.66,67 PMNs are essential for the
innate immunity and are the most abundant leukocyte in plasma.
In response to inﬂammatory stimuli, they migrate from plasma to
the affected tissue where they take part in the ﬁrst line of innate
immune response. The effect is mediated through the release of
enzymes from the granules and the production of compounds with
antimicrobial potential and inﬂammation regulatory effects.15 One
of the compounds is NET. PMNs can disintegrate their cell mem-
brane and release NETs to capture and kill invasive microorgan-
isms.47,68 The NETs are composed of relaxed DNA to which
histones and other effector molecules are bound.45 Eleven of the
46 proteins with statistically signiﬁcantly altered abundance in the
UC biopsies are associated with NET formation, and all were
measured with increased abundance. As no proteins unique to
NETs are known, we investigated if the PMNs were intact or
found as NETs. We stained the biopsy sections with a DNA stain
and investigated the sections by confocal microscopy, which al-
lowed us to achieve a higher resolution than with light micros-
copy. Again, the segmented cell nucleus of the PMNs was
apparent, and additionally, in biopsies from UC_4, we observed
NETs at 2 distinct locations. The proteomics data and microscopy
data demonstrate the increased abundance of PMNs in UC colon
tissue and NETs in biopsies from UC_4. This study is the ﬁrst to
directly observe NETs in UC colon tissue. Interestingly, the abun-
dances of several NET-associated histone proteins (H1e, H2A,
H2B, H3, and H4) were not found with increased abundance in
the UC biopsies.45 Additionally, histones H2A and H3 were found
to be more abundant in the UC colonic tissue by Han et al,20
indicating that NETs could have been present in the colonic tissue
obtained in this study as well. However, as histone proteins are an
essential part of nearly all cells, a relative increase in the abun-
dance of these proteins between the UC biopsies and controls as
a result of the presence of NETs might be too small to be detected.
NETs are part of the innate immune system’s response to
invading pathogens.47,68 Additionally, several of proteins found to
be more abundant in the UC colon tissue are directly involved in
the mucosal innate immune system response. However, the cause
for the immune response remains unknown, and no indications of
bacteria or epithelial cell disruption were detected by the histol-
ogy analysis, which should have been visible using confocal
microscopy. It cannot be ruled out that the immune reactions
could be caused by bacterial components capable of crossing
the intestinal barrier of epithelial cells, which is known to be
compromised in IBD where an increased epithelial permeability
has been described.10,69,70 However, it has been demonstrated that
aberrant formation of NETs might be involved in the pathogenesis
of autoimmunity and additionally might be formed during a num-
ber of activities, including exercise.71–73 Therefore, based on the
obtained data in this study, we can conclude that a chronic inﬂam-
mation is present in the tissue, even though the surface appears
normal. However, we cannot point to the origin of the inﬂamma-
tion or the target of the immune response.
Our ﬁndings demonstrate that even though remission has
been achieved on the surface of the UC colonic tissue, a chronic
condition is still present within the tissue. Poulsen et al18 per-
formed a 2-dimensional proteomics study of 20 patients with
UC where inﬂamed and noninﬂamed tissue from the same patient
with UC were compared, in contrast to the present study where
noninﬂamed tissue from several patients with UC was compared
with controls.18 Interestingly, the study by Poulsen et al18 found
that in contrast to the macroscopically different tissue, the pro-
teome of visually inﬂamed and noninﬂamed tissue was only
slightly different. Of the 43 protein spots identiﬁed with a different
abundance, the protein displaying the largest fold change was
glycerol-3-phosphate dehydrogenase, which was increased by
3.3-fold in the inﬂamed UC tissue compared with noninﬂamed
tissue, which is a minor change compared with the up to 219-fold
changes measured in the present study. Combined with the anal-
ysis of differences in colonic proteome between patients with UC
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and controls, we can conclude that the difference in proteome
between visually inﬂamed and noninﬂamed UC colonic tissue is
vastly smaller than the interpersonal difference between patients
with UC and controls. This indicates that changes are present in
the UC colonic tissue regardless of visible surface inﬂammation,
even in well-medicated patients with UC. A 2012 Danish
population-based cohort study of 300 patients with UC in the
period of 2003 to 2011, found that even though intensiﬁed immu-
nomodulation therapy is being used in Denmark, the ﬁrst time
recurrence rate, hospitalization rate, and surgical rates for patients
with UC have not decreased.74 This observation supports the
hypothesis that the administered treatment mostly is symptomatic.
However, it is worth mentioning that a study by Reich et al,75 in
which 481 patients with UC undergoing colectomy in the period
1998 to 2011 were included, showed that following the approval of
anti–tumor necrosis factor treatment for UC in 2005, the colectomy
rate has dropped.75 None of the patients included in this study had
active disease or was under treatment with anti-tumor necrosis
factor substances. Nonetheless, based on our study, we can con-
clude that chronic inﬂammation remains in the UC colonic tissue.
In conclusion, we have found an increased abundance of
PMNs in the UC colonic tissue, using high-throughput proteo-
mics, light microscopy, and confocal microscopy. Additionally,
we have for the ﬁrst time observed NETs, detected by proteomics
and veriﬁed by light microscopy at 2 distinct locations in a biopsy
from a patient with UC. Our ﬁndings demonstrate an activated
innate immune system in well-medicated patients with UC
without disease activity and the presence of chronic inﬂammation
in the morphologically normal tissue. Additionally, through
a comparison with other studies, we can conclude that the
proteome of inﬂamed and noninﬂamed tissue from the same
patient is much more similar compared with the proteome of
different individuals, indicating that a chronic condition is present
even in UC colonic tissue that appears normal during endoscopy.
However, no indications of bacterial inﬁltrations in the tissue were
found in the study. To increase our understanding of the UC and
IBD etiology, future studies should aim at investigating the
etiology of the immune reaction in the UC colonic tissue.
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